Squarepoint Ops LLC Acquires 957,305 Shares of Compass Therapeutics, Inc. $CMPX

Key Points

• Squarepoint Ops LLC significantly increased its Compass Therapeutics stake by purchasing 957,305 shares in the second quarter, bringing its total to 1,007,507 shares, or approximately 0.56% of the company. Institutional investors collectively own 68.43% of CMPX.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $11.77, despite mixed individual ratings.
• Compass Therapeutics shares opened at $1.96 and have declined 2.0%; the company also reported a quarterly loss of $0.13 per share, missing the $0.11 consensus estimate.

Squarepoint Ops LLC increased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 1,906.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,007,507 shares of the company's stock after purchasing an additional 957,305 shares during the period. Squarepoint Ops LLC owned approximately 0.56% of Compass Therapeutics worth $2,206,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Compass Therapeutics in the 2nd quarter worth $71,000. California State Teachers Retirement System increased its holdings in shares of Compass Therapeutics by 32.0% in the second quarter. California State Teachers Retirement System now owns 148,291 shares of the company's stock worth $325,000 after buying an additional 35,975 shares during the period. HB Wealth Management LLC purchased a new position in shares of Compass Therapeutics in the second quarter worth about $29,000. AXQ Capital LP lifted its stake in shares of Compass Therapeutics by 68.1% in the 2nd quarter. AXQ Capital LP now owns 42,118 shares of the company's stock valued at $92,000 after acquiring an additional 17,060 shares during the last quarter. Finally, Two Sigma Securities LLC bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $64,000. 68.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CMPX. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a research report on Monday, June 1st. Piper Sandler boosted their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They set a "buy" rating and a $5.00 price objective for the company. Wall Street Zen lowered shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Finally, Citigroup reissued a "market outperform" rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.77.

Compass Therapeutics Trading Down 2.0%

NASDAQ:CMPX opened at $1.96 on Tuesday. The company has a 50 day simple moving average of $2.21 and a two-hundred day simple moving average of $3.12. Compass Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $6.88. The company has a market cap of $352.98 million, a PE ratio of -4.90 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Research analysts forecast that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.